ArticleMedicine2026
Analysis of prognostic factors for advanced pancreatic neuroendocrine carcinoma: A population-based study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic neuroendocrine carcinoma (PNEC) is a rare and aggressive malignancy with poor prognosis. However, large-scale studies on the prognostic factors of PNEC remain limited. We retrospectively extracted clinical data of patients diagnosed with PNEC between 2004 and 2021 from the surveillance, epidemiology, and end results (SEER) database. Overall survival (OS) and cancer-specific survival (CSS) were analyzed using Kaplan-Meier method and compared by log-rank test. Univariate and multivariate Cox proportional-hazards regression models were employed to identify independent prognostic factors. Among 2089 included patients with PNEC, the median age was 61 years (range: 11-90 years). The median OS was 13.0 months, with 1-, 3-, and 5-year OS rates of 51.3%, 29.1%, and 20.1%, respectively. The median CSS was 14.0 months, with corresponding 1-, 3-, and 5-year CSS rates of 53.0%, 31.2%, and 21.9%, respectively. Multivariate analysis identified that advanced age (HR = 1.02, 95% CI: 1.01-1.03, P < .001), poor histological differentiation (HR = 1.35, 95% CI: 1.12-1.63, P = .002), primary tumor located in the head (HR = 1.28, 95% CI: 1.09-1.51, P = .003) or body (HR = 1.42, 95% CI: 1.15-1.75, P = .001) of the pancreas, regional lymph node metastasis (HR = 1.32, 95% CI: 1.14-1.53, P < .001), absence of primary site surgery (HR = 2.15, 95% CI: 1.82-2.54, P < .001), and absence of chemotherapy (HR = 1.87, 95% CI: 1.63-2.15, P < .001) were independent prognostic factors associated with worse OS and CSS. Patients with PNEC have poor prognosis with median survival of approximately 13 months. Several clinicopathological factors including age, tumor differentiation, tumor location, lymph node status, and treatment modalities were identified as independent prognostic indicators. These findings provide valuable insights for prognostic stratification and treatment decision-making in patients with PNEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.